StockData
SDGRNasdaqPharmaceutical PreparationsFiscal year ends December 31

Schrodinger, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.12+0.52 (+2.30%)

Close on Oct 19, 2026

Market cap
$1.75B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 5, 2026During market hours$58.90M$0.08–
Q1 FY2026
Ended Mar 31, 2026
May 5, 2026During market hours$58.60M$-0.81–
Q4 FY2025
Ended Dec 31, 2025
Feb 25, 2026During market hours$87.20M––
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025During market hours$54.30M$-0.45$-0.57
Q2 FY2025
Ended Jun 30, 2025
Aug 6, 2025During market hours$54.80M$-0.59$-0.65
Q1 FY2025
Ended Mar 31, 2025
May 7, 2025During market hours$59.60M$-0.82$-0.64
Q4 FY2024
Ended Dec 31, 2024
Feb 26, 2025During market hours$88.30M–$-0.24
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024Before market open$35.30M$-0.52$-0.87
Q2 FY2024
Ended Jun 30, 2024
Jul 31, 2024During market hours$47.30M$-0.74$-0.66
Q1 FY2024
Ended Mar 31, 2024
May 1, 2024During market hours$36.60M$-0.76$-0.86
Q4 FY2023
Ended Dec 31, 2023
Feb 28, 2024During market hours$74.10M–$-0.32

Company guidance

Outlook given with results on Aug 5, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
ACV growthfiscal year ending December 31, 202610% to 15% growthMaintained
ACV, excluding contribution ACVthird quarter of 2026$41.00M to $45.00MNew
ACVfiscal year ending December 31, 2026$218.00M to $228.00MMaintained
Drug discovery revenuefiscal year ending December 31, 2026$65.00M to $75.00MRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Schrodinger filed with the SEC